glioma

  •   George Lundberg, MD

    Research paper from the Journal of Neurosurgery curated by Editor in Chief George Lundberg, MD, who notes: 

    The extent of tumor resection—how much of the tumor is able to be removed—at the initial surgery is probably the most important factor in prognosis of glioblastoma. This academic research paper explores methods that help surgeons maximize tumor removal.

    Go to full paper published in the Journal of Neurosurgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from the Journal of Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Safety and potential adverse effects are serious issues with many cancer treatments. This academic paper outlines post-marketing research that reveals few adverse effects from a type of treatment known as tumor-treating fields (TTF) in brain malignancies.

    Go to full paper published in the Journal of Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from Cancers curated by Editor in Chief George Lundberg, MD, who notes: 

    Instead of focusing on “curing” cancer, the authors of this academic research paper focus on approaches to managing cancer as a chronic disease.

    Go to full paper published in Cancers.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from Journal of Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Tumor-treating fields (TTF) is a type of cancer treatment that uses alternating electric pulses. Its use for adults with high-grade gliomas remains controversial, and as outlined in this academic review paper, more high-quality research is needed.

    Go to full paper published in Journal of Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Announcement from the College of American Pathologists curated by Editor in Chief George Lundberg, MD, who notes: 

    What forms of testing should be done for diffuse gliomas? In this announcement, a global panel invites comments about proposals.

    Go to full announcement published by the College of American Pathologists.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD:

    A brainstem glioma is a very serious disease that is rare and mostly affects children. Diffuse pontine intrinsic glioma  (DPIG) is one type of brainstem glioma. For an authoritative, up-to-date, detailed, comprehensive, and unbiased overview of brainstem gliomas, check out this presentation and discussion. (You may be required to register for free to view it.)

     

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD:

    Most malignant brain tumors are gliomas, which begin in nerve-supporting cells known as glial cells. “Glioblastoma multiforme (GBM) is the most common and most malignant of the glial tumors,” according to this comprehensive presentation about GBM. Check it out for an authoritative, up-to-date, detailed, unbiased perspective. (You may be required to register for free to view the presentation.)

  •   Emma Shtivelman, PhD

    Excerpt:

    “Researchers at UCSF Benioff Children’s Hospitals are using next-generation genomic technology to develop targeted therapies for high-grade pediatric glioma.

    “Sabine Mueller, MD, PhD, adjunct associate professor of neurology, pediatrics and neurosurgery at University of California, San Francisco, and colleagues aim to treat as many as 44 children and young adults with this disease.”

    Go to full article published by Healio on Feb 3, 2019.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    Patient Foundation Collaboration to Advance ONC201 in DIPG and other H3 K27M-mutant Gliomas

    Musella Foundation, Cancer Commons, xCures and Oncoceutics announced the initiation of a collaboration to develop ONC201 as a new treatment for diffuse intrinsic pontine glioma (DIPG) and other H3 K27M-mutant gliomas. Critical to the collaboration is $1M in funding from… Read more »

  •   Emma Shtivelman, PhD

    Excerpt from The ASCO Post:

    “In a phase II trial funded by the European Organisation for Research and Treatment of Cancer and reported in The Lancet Oncology, van den Bent et al found no evidence of a survival benefit with the addition of bevacizumab (Avastin) to temozolomide in patients with a first recurrence of World Health Organization grade II or III glioma without the 1p/19q codeletion.

    “In the open-label trial, conducted at 32 European centers, 155 patients were randomized between February 2011 and July 2015 to receive either temozolomide at 150 to 200 mg/m² on days 1 to 5 every 4 weeks for a maximum of 12 cycles (n = 77) or the same temozolomide regimen plus bevacizumab at 10 mg/kg every 2 weeks until disease progression (n = 78). Previous chemotherapy must have been stopped at least 6 months before enrollment, and radiotherapy, at least 3 months before enrollment. Overall, 44% of patients in the combination group and 47% in the temozolomide group had grade III disease.”

    Go to full article published by The ASCO Post on Aug 20, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.